CJC-1295 vs MGF.

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), based on the first 29 amino acids of human GHRH (GRF 1-29) with several amino-acid substitutions that resist enzymatic degradation. The name is used for two distinct molecules: "CJC-1295 with DAC," which carries a Drug Affinity Complex (a maleimidoproprionic acid linker) that covalently binds to circulating albumin to dramatically prolong its action; and "CJC-1295 without DAC" (often sold as "modified GRF 1-29" or "Mod GRF 1-29"), which lacks the albumin-binding linker. It was originally developed by the Canadian biotech company ConjuChem as an investigational therapeutic.

MGF is a splice variant of insulin-like growth factor 1 (IGF-1), designated IGF-1Ec in humans and IGF-1Eb in rodents, produced locally in skeletal muscle in response to mechanical loading or damage. The synthetic 'MGF' peptide that is sold and studied is the unique C-terminal E-domain (Ec) portion, not the full IGF-1 molecule. It was characterized largely by Geoffrey Goldspink's group, who proposed it as an autocrine and paracrine signal that activates muscle satellite cells. It remains a preclinical research compound with no approved use.

As a GHRH analog, CJC-1295 binds the GHRH receptor on somatotroph cells of the anterior pituitary, activating Gs-protein/cAMP/PKA signaling to stimulate synthesis and pulsatile release of endogenous growth hormone (GH), which in turn raises hepatic insulin-like growth factor 1 (IGF-1). The four substitutions in the GRF(1-29) backbone (notably at the position-2 alanine that is the dipeptidyl peptidase-IV cleavage site) protect the peptide from rapid breakdown, extending the half-life of the non-DAC form to roughly 30 minutes versus minutes for native GHRH. In the DAC version, the maleimide linker forms a covalent bond with cysteine-34 of serum albumin, creating a long-circulating depot; because it raises GH in a more sustained rather than sharply pulsatile manner, it is described as increasing trough and mean GH while largely preserving the body's own pulse pattern.

The mechanistic hypothesis is that the MGF E-peptide, generated by a reading-frame shift in IGF-1 splicing after mechanical stress, activates satellite (muscle stem) cells to proliferate through a receptor thought to be distinct from the classical IGF-1 receptor. In this model MGF acts as a local kick-start for repair that precedes the mature IGF-1 which later drives differentiation. This mechanism is characterized in cell and animal models, and even there it is contested. Several independent laboratories have been unable to reproduce a direct proliferative effect of the isolated E-peptide.

The principal human evidence is a single 2006 Phase 1 study in healthy adults by Teichman et al. (J Clin Endocrinol Metab, PMID 16352683), which reported that one subcutaneous dose of CJC-1295 with DAC produced dose-dependent increases in mean plasma GH of roughly 2- to 10-fold for 6 days or more and IGF-1 increases of about 1.5- to 3-fold for 9-11 days, with an estimated half-life of 5.8-8.1 days and IGF-1 staying above baseline up to 28 days after repeated dosing. ConjuChem advanced the DAC compound into a Phase 2 trial in HIV-associated visceral obesity (ClinicalTrials.gov NCT00267527), but that 12-week trial was terminated in 2006. Beyond these, robust controlled human efficacy and long-term safety data are essentially absent; there are no large or long-term trials, no published outcomes for the non-DAC "modified GRF 1-29" form in humans, and much of the mechanistic rationale rests on GHRH-class pharmacology rather than direct trials of this molecule. Claims about body composition, recovery, or anti-aging benefit are not supported by published controlled human outcome data.

Early work from Goldspink and colleagues in the late 1990s and 2000s reported that mechanically induced IGF-1Ec/MGF expression tracked with muscle hypertrophy and repair, and some cell studies suggested the E-peptide activated satellite cells. The foundational experiments were expression studies rather than treatment studies. Rabbit skeletal muscle subjected to stretch and electrical stimulation showed a shift in IGF-1 splicing toward the alternative variant (PMID 10087355), and rodent muscle subjected to local damage showed the same splicing shift alongside satellite cell activation (PMID 12692175). Those designs establish a correlation between a mechanical stimulus and a transcript, in small animal groups, over short time courses, without blinding and without any peptide being administered. They do not show that giving the isolated E-peptide does anything. That story is directly challenged by Fornaro et al. in the American Journal of Physiology-Endocrinology and Metabolism (2014, PMID 24253050), who found that the MGF E-peptide at concentrations up to 500 ng/mL had no apparent effect on the proliferation of C2C12 myoblasts or primary human muscle stem cells, whereas mature IGF-1 did. That paper tested synthetic E-peptide obtained from more than one source and included the positive control that much of the earlier literature lacked, which is why it carries substantial weight against the original claim. The contrast with better-characterized molecules in the same family is stark. Mature IGF-1 has decades of receptor pharmacology behind it, and its recombinant form mecasermin is an approved drug for severe primary IGF-1 deficiency, with defined pharmacokinetics, a known hypoglycemia risk, and labeled monitoring requirements. MGF has none of that. There are essentially no controlled human trials of synthetic MGF for muscle growth or repair, no human pharmacokinetic data, no confirmed receptor, no toxicology package, and no outcome data of any kind. The evidence base is preclinical, mixed, and negative in key experiments.

In the short Phase 1 work, CJC-1295 with DAC was described as generally well tolerated, with the kinds of effects expected from GHRH-class agents (e.g., injection-site reactions, flushing, headache); however, this reflects small numbers and short follow-up. The Phase 2 HIV trial (NCT00267527) was terminated in 2006, and a participant death during the program drew scrutiny, though available reporting attributed that death to pre-existing coronary disease rather than establishing causation by the drug; the episode underscores how thin the safety record is. Sustained elevation of GH/IGF-1 carries class-level theoretical concerns familiar from growth-hormone pharmacology, including fluid retention, joint/muscle pain, insulin resistance and elevated blood glucose, and a theoretical concern about promoting growth of existing malignancy; long-term safety in humans is simply unknown. Much material sold as "CJC-1295" online is from unregulated sources with no purity, sterility, or identity guarantees, adding contamination and mislabeling risks.

There is no meaningful human safety data for injected synthetic MGF. No clinical trial has been conducted, so there is no reported adverse-event profile, no established tolerated exposure, no immunogenicity assessment, and no chronic toxicology. Theoretical concerns follow from IGF-1 biology, including unregulated growth-factor signaling and the possibility of promoting proliferation of pre-existing tumor cells, although the isolated E-peptide's own activity is uncertain. That uncertainty cuts both ways. A peptide that does not measurably act on muscle stem cells in culture is unlikely to carry the full risk profile of mature IGF-1, but it is also not established to be inert, and the receptor it supposedly acts through has never been identified, which makes off-target prediction impossible. Injected peptides carry generic risks independent of the sequence, including local reactions, sterile abscess, infection from non-sterile preparation, and antibody formation against a foreign or modified sequence. Pegylated versions sold as PEG-MGF add a further unknown, since polyethylene glycol conjugates raise tissue-accumulation and anti-PEG antibody questions that have not been examined for this molecule at all. Material sold online as MGF or PEG-MGF is unregulated and of unverified identity and purity, and independent testing of the grey peptide market has repeatedly found mislabeled contents, under-filled vials, and bacterial contamination. Any legitimate study would require sterility and endotoxin testing of the material, immunogenicity monitoring, measurement of the IGF-1 axis, and exclusion of participants with a cancer history before first exposure. Human safety is uncharacterized.

CJC-1295 (with or without DAC) has never been approved by the FDA or any major regulatory agency for any indication and remains an investigational compound that did not complete clinical development. It is not an approved medicine; it is sold only as a "research chemical," and GHRH analogs/GH secretagogues of this type are prohibited in sport by the World Anti-Doping Agency.

MGF is not approved by the FDA or any regulator and holds no marketing authorization for any indication. It is sold only as a research chemical. Growth-factor peptides of this type are prohibited in sport by WADA.